Puma Biotechnology Inc. sell nvestor
Start price
04.03.23
/
50%
€3.09
Target price
04.03.24
€1.00
Performance (%)
-4.21%
End price
16.09.23
€2.96
Summary
This prediction ended on 16.09.23 with a price of €2.96. With a performance of -4.21%, the SELL prediction for Puma Biotechnology Inc. by nvestor was down slightly. nvestor has 50% into this predictionPuma Biotechnology is a publicly traded biopharmaceutical company that develops innovative cancer therapies targeting the most aggressive and difficult-to-treat forms of the disease. Puma's lead product is Nerlynx, an oral medication approved for the treatment of HER2-positive breast cancer, and the company also has a number of other promising drugs in its pipeline. Founded in 2010, Puma is headquartered in Los Angeles, California, and its shares trade on the NASDAQ exchange under the ticker symbol PBYI.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Puma Biotechnology Inc. | -3.278% | -3.278% | 86.996% |
| iShares Core DAX® | 2.594% | -1.861% | 13.242% |
| iShares Nasdaq 100 | 3.553% | -2.064% | 38.293% |
| iShares Nikkei 225® | 0.687% | -8.704% | 17.510% |
| iShares S&P 500 | 2.209% | -1.988% | 27.632% |
Comments by nvestor for this prediction
In the thread Puma Biotechnology Inc. diskutieren
In the thread Trading Puma Biotechnology Inc.
Stopped prediction by nvestor for Puma Biotechnology Inc.
Puma Biotechnology Inc.
Start price
Target price
Perf. (%)
€4.55
20.01.24
20.01.24
€2.00
20.01.25
20.01.25
-1.54%
03.02.24
03.02.24
